Novartis Jumps 6% as MS Drug Meets Goals in Two Phase 3 Trials
Novartis (NYSE:NVS) shares rose 6% to $161.10 after its MS drug, remibrutinib, succeeded in two Phase 3 trials, showing fewer relapses and brain lesions. The company reported slower disability progression, potentially boosting its market position. Remibrutinib is already sold as Rhapsido for chronic hives, with Q2 sales of $64 million. Full results are expected in October, followed by global regulatory submissions.
How this was made
The 30-second read
Why it matters
The Phase 3 data shows fewer relapses and lesions versus teriflunomide, with no new liver safety signals, prompting a 6% price jump.
Market read
First‑report trial success for a major pharma, immediate price impact, and potential regulatory upside.
What to watch
Potential competition from other oral MS drugs and the modest current sales of remibrutinib for hives.
Background
Novartis (NVS) is a Swiss multinational with a broad oncology and immunology portfolio. Remibrutinib is already marketed for chronic hives (Rhapsido).
Ticker impact
Novartis reported positive Phase 3 results for remibrutinib in multiple sclerosis, driving a 6% stock jump.
Expect continued buying pressure, potential further gains if regulatory filings proceed.
Phase 3 success is a material catalyst for a large pharma; the stock already rose 6% on the news.
Market effects
Boosts outlook for MS therapeutics and may lift peers in neuro‑immunology.
Positive for European pharma stocks, especially Swiss listings.
Highlights continued strength of biotech pipelines worldwide.
Counterpoint
Skeptics may point to prior safety concerns and the need for regulatory approval before pricing in gains.
Key entities
- companyNovartis AG
Swiss pharmaceutical giant reporting the trial results.
- drugRemibrutinib
Oral MS candidate showing positive Phase 3 outcomes.
